Trials / Completed
CompletedNCT05262764
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
Post Marketing Surveillance on Long Term Drug Use of JARDIANCE® Tablets in Patients With Chronic Heart Failure in Japan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,200 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JARDIANCE® | Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS). |
Timeline
- Start date
- 2022-04-15
- Primary completion
- 2024-06-21
- Completion
- 2024-06-28
- First posted
- 2022-03-02
- Last updated
- 2026-03-24
- Results posted
- 2025-08-06
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05262764. Inclusion in this directory is not an endorsement.